IN10018

IN10018 (BI853520) is a small-molecule drug developed by InxMed (Shanghai) and InventisBio. The sponsor describes its target as FAK, which OnCo does not yet have a target page for. The sponsor states: FAK (focal adhesion kinase) inhibitor. ClinicalTrials.gov describes the intervention as: Based on existing clinical data, the RP2D of IN10018 as monotherapy and in combination with chemotherapy, targeted therapy, and immunotherapy is 100 mg QD. For RNK08954 as monotherapy, the Maximum Tolerated Dose (MTD) was not reached during. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07174908 (A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation), in non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and small-cell lung cancer. The largest, NCT07174908, plans to enrol 400 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.